REVIEW ARTICLE Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy

Atherosclerosis is a dynamic process and timely introduction of pharmacological treatment can have a significant bearing on the patient's health and outcome. In addition to treating the culprit lesion mechanically, admission for percutaneous coronary interventions (PCI) for coronary artery dise...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of clinical practice (Esher) Vol. 59; no. 9; p. 1070
Main Authors Jaumdally, R, Lip, G Y H, Varma, C
Format Journal Article
LanguageEnglish
Published London Hindawi Limited 01.09.2005
Subjects
Cardiovascular disease
Drug therapy
Inhibitor drugs
Medical procedures
Statins
Online AccessGet full text

Cover

More Information
Summary:Atherosclerosis is a dynamic process and timely introduction of pharmacological treatment can have a significant bearing on the patient's health and outcome. In addition to treating the culprit lesion mechanically, admission for percutaneous coronary interventions (PCI) for coronary artery disease (CAD) gives an opportunity for the interventional cardiologist to optimize medical therapy. The aim of this review is to provide an overview of the current medical literature pertaining to cardiovascular (CV) risk reduction and vascular event prevention in the setting of PCI, with emphasis on antiplatelet therapies, beta-blockers, HMG-Co A reductase inhibitors (statins) and angiotensin-converting enzyme inhibitors, with regard to therapy optimization during PCI and for chronic CAD. We discuss the effects of these oral therapies in reducing ischaemic events, thus augmenting the benefits of PCI, as well as preventing recurrent CV events after the procedure. [PUBLICATION ABSTRACT]
ISSN:1368-5031
1742-1241
DOI:10.1111/j.1742-1241.2005.00608.x